Cancer Therapy : Clinical Phase II Study of Everolimus ( RAD 001 ) in Previously Treated Small Cell Lung Cancer

@inproceedings{Tarhini2010CancerT,
  title={Cancer Therapy : Clinical Phase II Study of Everolimus ( RAD 001 ) in Previously Treated Small Cell Lung Cancer},
  author={Ahmad A Tarhini and Athanasios A Kotsakis and W. E. Gooding and Yongli Shuai and Daniel P Petro and David P Friedland and Chandra Prakash Belani and Sanja Dacic and Athanassios Argiris},
  year={2010}
}
Purpose: Mammalian target of rapamycin (mTOR) is a promising target in small cell lung cancer (SCLC). We designed a phase II study of everolimus, an mTOR inhibitor, in previously treated, relapsed 

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1996
View 6 Excerpts
Highly Influenced

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2008
View 5 Excerpts
Highly Influenced

Phase I evaluation of lapatinib and everolimus in patients with advanced malignancies: Southwest Oncology Group trial S0528.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2009
View 2 Excerpts

Similar Papers

Loading similar papers…